In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Brought to you by

Roche licenses Memory Pharma's compound to treat Alzheimer's

Executive Summary

Memory Pharmaceuticals (neurological and psychiatric therapeutics) has licensed Roche exclusive worldwide development rights to compounds in preclinical studies to treat Alzheimer's disease. The companies will also co-develop compounds in the same class for other indications including depression and anxiety.
Deal Industry
  • Biotechnology
  • Pharmaceuticals
Deal Status
  • Final
Deal Type
  • Alliance
    • R+D and Marketing-Licensing
    • Includes Contract
    • Co-Promotion
    • Includes Equity

Related Companies